Kuek A, Hazleman BL, Ostör AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251-260. https://doi.org/10.1136/pgmj.2006.052688

Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11 Suppl 1(Suppl 1):S1. https://doi.org/10.1186/ar2666

Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. https://doi.org/10.1136/annrheumdis-2019-216655

Government of Alberta. Biosimilar drugs. https://www.alberta.ca/biosimilar-drugs.aspx (accessed Oct 28, 2020).

British Columbia Government. Biosimilars FAQ for prescribers. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/biosimilars-initiative-prescribers/biosimilars-faq-prescribers#PSP (accessed Jul 7, 2020)

Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111-5117. https://doi.org/10.1182/blood-2012-04-425744

Kim JW, Jung JY, Suh CH. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. Expert Opin Biol Ther. 2021;21(1):57-73. https://doi.org/10.1080/14712598.2020.1812575

Mansell K, Bhimji H, Eurich D, Mansell H. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis. BMC Health Serv Res. 2019;19(1):827. https://doi.org/10.1186/s12913-019-4680-2

Mezones-Holguin E, Gamboa-Cardenas RV, Sanchez-Felix G, et al. Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country. Front Pharmacol. 2019;10:1010. https://doi.org/10.3389/fphar.2019.01010

Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs. 2018;78(4):463-478. https://doi.org/10.1007/s40265-018-0881-y

Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304-2316. https://doi.org/10.1016/s0140-6736(17)30068-5

Gerdes S, Thaçi D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018;32(3):420-427. https://doi.org/10.1111/jdv.14605

Toussirot E, Marotte H. Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?. RMD Open. 2017;3(2):e000492. https://doi.org/10.1136/rmdopen-2017-000492

Kristensen LE, Alten R, Puig L, et al. Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. BioDrugs. 2018;32(5):397-404. https://doi.org/10.1007/s40259-018-0306-1

FDA. Biosimilar and interchangeable biologics: more treatment choices. https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices (accessed Jul 8, 2020).

Foreman E, Patel H, Siderov J, Harchowal J, Bubalo J, Chan A. A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners. J Oncol Pharm Pract. 2020;26(3_suppl):22-32. https://doi.org/10.1177/1078155220913098

Scott BJ, Klein AV, Wang J. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. J Clin Pharmacol. 2015;55(Suppl 3):S123-S132. https://doi.org/10.1002/jcph.339

Endrenyi L, Jamali F, Loebenberg R. Subsequent Entry Biologics in Canada: Current State of the Science. J Pharm Pharm Sci. 2015;18(2):177-183. https://doi.org/10.18433/j38s3h

Nominal group technique (ngt): nominal brainstorming steps. https://asq.org/quality-resources/nominal-group-technique (accessed Oct 19, 2020).

Harvey N, Holmes CA. Nominal group technique: an effective method for obtaining group consensus. Int J Nurs Pract. 2012;18(2):188-194. https://doi.org/10.1111/j.1440-172x.2012.02017.x

McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016;38(3):655-662. https://doi.org/10.1007/s11096-016-0257-x

CDC. Gaining consensus among stakeholders through the nominal group technique. https://www.cdc.gov/healthyyouth/evaluation/pdf/brief7.pdf (accessed Jun 3, 2021).

Charmaz K, Belgrave LL. Grounded theory. In: Ritzer G, ed. The Blackwell encyclopedia of sociology. Hoboken, NJ: Wiley; 2015. ISBN: 9781405124331

Interactive presentation software: Mentimeter. https://www.mentimeter.com/ (accessed Oct 28, 2020).

Pouillon L, Socha M, Demore B, et al. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018;14(9):739-749. https://doi.org/10.1080/1744666x.2018.1512406

Edwards CJ, Hercogová J, Albrand H, Amiot A. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther. 2019;19(10):1001-1014. https://doi.org/10.1080/14712598.2019.1610381

The Arthritis Society. The Arthritis Society position on biosimilars. https://www.arthritis.ca/AS/media/pdf/Treatment/Biosimilars-Position-Paper-January-2018-FINAL-EN.PDF (accessed Oct 28, 2020).

Rezk MF, Pieper B. Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect. Rheumatol Ther. 2017;4(2):209-218. https://doi.org/10.1007/s40744-017-0085-z

Kay J, Schoels MM, Dörner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165-174. https://doi.org/10.1136/annrheumdis-2017-211937

Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clin Pharmacol Ther. 2020;108(4):734-755. https://doi.org/10.1002/cpt.1836

Vandenplas Y, Simoens S, Van Wilder P, Vulto AG, Huys I. Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals (Basel). 2021;14(2):117. https://doi.org/10.3390/ph14020117

Abbvie Corporation. Humira Product Monograph. https://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/HUMIRA_PM_EN.pdf (accessed Oct 28, 2020).

ULC PC. Xeljanz Product Monograph. https://www.pfizer.ca/sites/default/files/201910/XELJANZ_PM_E_230976_24Oct2019.pdf (accessed Oct 28, 2020).

Roche H-L. Rituxan Product Monograph. Toxicology. https://www.rochecanada.com/PMs/Rituxan/RituxanIV_PM_E.pdf (accessed Oct 28, 2020).

Canada B-MS. Orencia Product monograph. https://www.bms.com/assets/bms/ca/documents/productmonograph/ORENCIA_EN_PM.pdf (accessed Oct 28, 2020).

Swedish Orphan Biovitrum. Kinaret Product monograph. https://pdf.hres.ca/dpd_pm/00044494.PDF (accessed Oct 28, 2020).

Bolognese JA, Schnitzer TJ, Ehrich EW. Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. Osteoarthr Cartil. 2003;11(7):499-507. https://doi.org/10.1016/S1063-4584(03)00082-7

Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am. 2009;35(4):773-778. https://doi.org/10.1016/j.rdc.2009.10.008